1 |
2-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-n-(methylsulfonyl)actamide |
- |
- |
- |
- |
086 1件: 86 💬 |
2 |
90 mg hydrocortisone acetate suppository with sephure suppository applicator |
Acetate |
2件: D00088 D00088, D00165 D00165 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
097 1件: 97 💬 |
3 |
A novel synthetic, orally-administered, non-peptide small molecule, which acts as |
- |
- |
- |
- |
254 1件: 254 💬 |
4 |
A-dopamine |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
5 |
Abatacept active treatment |
Abatacept |
1件: D03203 D03203 💬 |
CD80 2件: CD80, CD86 💬 |
Allograft rejection 12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
050 1件: 50 💬 |
6 |
Abatacept, rituximab or tocilizumab |
Abatacept |
3件: D02596 D02596, D02994 D02994, D03203 D03203 💬 |
CD80 4件: CD80, CD86, IL6R, MS4A1 💬 |
Allograft rejection 24件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
7 |
Act |
- |
- |
- |
- |
013 1件: 13 💬 |
8 |
Act - 064992 |
- |
- |
- |
- |
086 1件: 86 💬 |
9 |
Act-050089 |
- |
- |
- |
- |
086 1件: 86 💬 |
10 |
Act-050089 (ro 61-0612) |
- |
- |
- |
- |
086 1件: 86 💬 |
11 |
Act-064992 |
- |
- |
- |
- |
051 5件: 51, 85, 86, 88, 210 💬 |
12 |
Act-064992 (macitentan) |
Macitentan |
1件: D10135 D10135 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
085 1件: 85 💬 |
13 |
Act-064992d |
- |
- |
- |
- |
086 1件: 86 💬 |
14 |
Act-1 |
- |
- |
- |
- |
013 1件: 13 💬 |
15 |
Act-128800 |
Ponesimod |
1件: D11215 D11215 💬 |
S1PR1 1件: S1PR1 💬 |
FoxO signaling pathway 3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
013 1件: 13 💬 |
16 |
Act-128800 dose 1 |
Ponesimod |
1件: D11215 D11215 💬 |
S1PR1 1件: S1PR1 💬 |
FoxO signaling pathway 3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
013 1件: 13 💬 |
17 |
Act-128800 dose 2 |
Ponesimod |
1件: D11215 D11215 💬 |
S1PR1 1件: S1PR1 💬 |
FoxO signaling pathway 3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
013 1件: 13 💬 |
18 |
Act-128800 dose 3 |
Ponesimod |
1件: D11215 D11215 💬 |
S1PR1 1件: S1PR1 💬 |
FoxO signaling pathway 3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
013 1件: 13 💬 |
19 |
Act-178418 |
- |
- |
- |
- |
086 1件: 86 💬 |
20 |
Act-293987 |
- |
- |
- |
- |
051 3件: 51, 86, 88 💬 |
21 |
Act-293987 (ns-304) |
- |
- |
- |
- |
086 1件: 86 💬 |
22 |
Act-293987 / jnj-67896049 |
- |
- |
- |
- |
084 1件: 84 💬 |
23 |
Act-334441 |
- |
- |
- |
- |
049 1件: 49 💬 |
24 |
Act-385781a |
- |
- |
- |
- |
086 1件: 86 💬 |
25 |
Act-385781a (actelion epoprostenol) |
Epoprostenol |
2件: D00106 D00106, D01337 D01337 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
26 |
Act-434964 |
- |
- |
- |
- |
019 1件: 19 💬 |
27 |
Actemra |
- |
- |
- |
- |
046 2件: 46, 107 💬 |
28 |
Actemra(eu-licensed) |
- |
- |
- |
- |
046 1件: 46 💬 |
29 |
Actemra, mra |
- |
- |
- |
- |
107 1件: 107 💬 |
30 |
Acteoside |
Acteoside |
- |
- |
- |
066 1件: 66 💬 |
31 |
Acth |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
013 5件: 13, 66, 145, 193, 222 💬 |
32 |
Acth (acthar) gel |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
066 1件: 66 💬 |
33 |
Acthar |
- |
- |
- |
- |
002 9件: 2 , 13, 14, 46, 49, 50, 66, 84, 222 💬 |
34 |
Acthar 80 unit injection |
- |
- |
- |
- |
066 1件: 66 💬 |
35 |
Acthar gel |
- |
- |
- |
- |
013 6件: 13, 46, 49, 50, 84, 222 💬 |
36 |
Acthar gel (acth) |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
013 1件: 13 💬 |
37 |
Acthar gel (adrenocorticotropic hormone) |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
084 1件: 84 💬 |
38 |
Acthar gel 40 units twice weekly |
- |
- |
- |
- |
084 1件: 84 💬 |
39 |
Acthar gel 80 units twice weekly. |
- |
- |
- |
- |
084 1件: 84 💬 |
40 |
Acthar high dose (80 u) |
- |
- |
- |
- |
049 1件: 49 💬 |
41 |
Acthar injectable product |
- |
- |
- |
- |
046 1件: 46 💬 |
42 |
Acthar low dose (40 u) |
- |
- |
- |
- |
049 1件: 49 💬 |
43 |
Acthrel |
- |
- |
- |
- |
075 1件: 75 💬 |
44 |
Actimmune |
- |
- |
- |
- |
326 1件: 326 💬 |
45 |
Actimmune registry |
- |
- |
- |
- |
326 1件: 326 💬 |
46 |
Active bmn 111: daily subcutaneous injection of 15 ug/kg of bmn 111 |
- |
- |
- |
- |
276 1件: 276 💬 |
47 |
Active comparator |
- |
- |
- |
- |
006 2件: 6 , 46 💬 |
48 |
Active comparator receiving extavia® |
- |
- |
- |
- |
013 1件: 13 💬 |
49 |
Active control |
- |
- |
- |
- |
013 1件: 13 💬 |
50 |
Active drug (biib014) at 10, 30, 100, or 300 mg once daily. |
- |
- |
- |
- |
006 1件: 6 💬 |
51 |
Active drug: pimavanserin 17mg (2 strength tablets) |
Pimavanserin |
- |
- |
- |
006 1件: 6 💬 |
52 |
Active group |
- |
- |
- |
- |
097 1件: 97 💬 |
53 |
Active investigational treatment ent-01 |
- |
- |
- |
- |
006 1件: 6 💬 |
54 |
Active topical ns2 1% dermatologic cream |
- |
- |
- |
- |
160 1件: 160 💬 |
55 |
Active treatment group 7% hypertonic saline |
- |
- |
- |
- |
299 1件: 299 💬 |
56 |
Actonel 5mg film coated tablets |
- |
- |
- |
- |
274 1件: 274 💬 |
57 |
Actonel once a week 35 mg film-coated tablets |
- |
- |
- |
- |
274 1件: 274 💬 |
58 |
Actonel once a week 5mg film coated tablets |
- |
- |
- |
- |
113 1件: 113 💬 |
59 |
Actonel/optinate 5mg film-coated tablets |
- |
- |
- |
- |
274 1件: 274 💬 |
60 |
Actos (pioglitazone) |
Pioglitazone |
2件: D00945 D00945, D08378 D08378 💬 |
PPARG 1件: PPARG 💬 |
AMPK signaling pathway 9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
013 1件: 13 💬 |
61 |
Actos 15 mg |
- |
- |
- |
- |
002 1件: 2 💬 |
62 |
Actos 30 mg |
- |
- |
- |
- |
002 1件: 2 💬 |
63 |
Actos 45 mg |
- |
- |
- |
- |
002 1件: 2 💬 |
64 |
Actrapid 100 iu/ml, solution for injection in a vial |
- |
- |
- |
- |
299 1件: 299 💬 |
65 |
Actrapid penfill 100ui/ml |
- |
- |
- |
- |
299 1件: 299 💬 |
66 |
Actriia-igg1fc |
- |
- |
- |
- |
086 1件: 86 💬 |
67 |
Adalimuab, etanercept, tocilizumab, or abatacept |
Abatacept |
3件: D00742 D00742, D02596 D02596, D03203 D03203 💬 |
CD80 5件: CD80, CD86, IL6R, LTA, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 77件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 1件: 46 💬 |
68 |
Adjuvant without active component |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
69 |
Adrenocorticotrophic hormone acth |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
222 1件: 222 💬 |
70 |
Adrenocorticotropic hormone (acth) gel (h.p. acthar®) |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
013 1件: 13 💬 |
71 |
Anti baff (b cell activating factor) |
- |
- |
- |
- |
049 1件: 49 💬 |
72 |
Antimicrobial therapy: co-trimoxazole or doxycycline |
Doxycycline |
5件: D00307 D00307, D02129 D02129, D03903 D03903, D03904 D03904, D07876 D07876 💬 |
- |
- |
085 1件: 85 💬 |
73 |
Anxiety/depression and work and activities |
- |
- |
- |
- |
013 1件: 13 💬 |
74 |
Behavioral: bci-fit active querying |
- |
- |
- |
- |
002 3件: 2 , 6 , 17 💬 |
75 |
Behavioral: physical activity together for pwms and their cgs (pat-ms) |
- |
- |
- |
- |
013 1件: 13 💬 |
76 |
Behavioral: role of dopamine |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
77 |
Biologically active human fecal microbiota |
- |
- |
- |
- |
097 1件: 97 💬 |
78 |
Bromocriptine and other dopamine agonists |
Bromocriptine |
4件: D00633 D00633, D00780 D00780, D03165 D03165, D07870 D07870 💬 |
DRD1 6件: DRD1, DRD2, DRD3, DRD4, DRD5, PRL 💬 |
Alcoholism 15件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
79 |
Bt-11 active |
- |
- |
- |
- |
096 2件: 96, 97 💬 |
80 |
Cerebral dopamine neurotrophic factor |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
81 |
Cfz533 active - cohort 1 |
- |
- |
- |
- |
053 1件: 53 💬 |
82 |
Cfz533 active - cohort 2 |
- |
- |
- |
- |
053 1件: 53 💬 |
83 |
Cfz533 active - cohort 3 |
- |
- |
- |
- |
053 1件: 53 💬 |
84 |
Cfz533 active -cohort 3 |
- |
- |
- |
- |
053 1件: 53 💬 |
85 |
Cjnj-68150420-zzz-g001 (act- 064992d) |
- |
- |
- |
- |
086 1件: 86 💬 |
86 |
Cjnj-68150420-zzz-g001 (act-064992d) |
- |
- |
- |
- |
086 1件: 86 💬 |
87 |
Cjnj-68150420-zzz-g001(act-064992d) |
- |
- |
- |
- |
086 1件: 86 💬 |
88 |
Combination oral budesonide and rectal hydrocortisone |
Budesonide |
2件: D00088 D00088, D00246 D00246 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
097 1件: 97 💬 |
89 |
Combination product: active treatment with dual therapy |
- |
- |
- |
- |
002 1件: 2 💬 |
90 |
Combination product: twice daily 90 mg hydrocortisone acetate suppository administered with sephure applicator |
Acetate |
2件: D00088 D00088, D00165 D00165 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
097 1件: 97 💬 |
91 |
Continuous release dopamine agonists |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
92 |
Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone) |
Acetate |
21件: D00088 D00088, D00292 D00292, D00472 D00472, D00473 D00473, D00973 D00973, D00975 D00975, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D01998 D01998, D02156 D02156, D02174 D02174, D02591 D02591, D02592 D02592, D03301 D03301, D07749 D07749 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
93 |
Cortef (hydrocortisone) |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
083 1件: 83 💬 |
94 |
Corticoids+ tocilizumab 8mg/kg/4 weeks |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
041 1件: 41 💬 |
95 |
Corticotropin |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
002 7件: 2 , 13, 46, 75, 78, 84, 222 💬 |
96 |
Corticotropin-releasing hormone |
Corticorelin |
2件: D00146 D00146, D03905 D03905 💬 |
CRHR1 3件: CRHR1, CRHR2, MC2R 💬 |
Aldosterone synthesis and secretion 6件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
075 1件: 75 💬 |
97 |
Decrease tocilizumab, abatacept |
Abatacept |
2件: D02596 D02596, D03203 D03203 💬 |
CD80 3件: CD80, CD86, IL6R 💬 |
Allograft rejection 24件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
98 |
Device: actimyo recording |
- |
- |
- |
- |
006 1件: 6 💬 |
99 |
Device: activated smart device |
- |
- |
- |
- |
299 1件: 299 💬 |
100 |
Device: active stimulation |
- |
- |
- |
- |
046 1件: 46 💬 |
101 |
Device: active tdcs |
- |
- |
- |
- |
006 1件: 6 💬 |
102 |
Device: active tpcs |
- |
- |
- |
- |
006 1件: 6 💬 |
103 |
Device: activity monitor |
Methamidophos |
- |
- |
- |
113 1件: 113 💬 |
104 |
Device: de-activated smart device |
- |
- |
- |
- |
299 1件: 299 💬 |
105 |
Device: nanocrystalline silver (acticoat) |
Silver |
- |
- |
- |
035 2件: 35, 162 💬 |
106 |
Device: omnidirectional accelerometer monitor (3x3 cm and 16 g, actical®, philips respironics) |
Methamidophos |
- |
- |
- |
118 1件: 118 💬 |
107 |
Device: wristband physical activity monitor |
Methamidophos |
- |
- |
- |
013 1件: 13 💬 |
108 |
Diagnostic test: disease activity |
- |
- |
- |
- |
046 1件: 46 💬 |
109 |
Diagnostic test: dm1-activc |
- |
- |
- |
- |
113 1件: 113 💬 |
110 |
Diagnostic test: fibrinogen plasma concentration, coagulation factor xiii activity |
Factor XIII (human) |
- |
- |
- |
288 1件: 288 💬 |
111 |
Dopamine |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 3件: 6 , 7 , 74 💬 |
112 |
Dopamine agent |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
113 |
Dopamine agonist treatment |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
074 1件: 74 💬 |
114 |
Dopamine agonists |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
074 1件: 74 💬 |
115 |
Dopamine agonists (pramipexole, ropirinole) |
Dopamine |
4件: D00559 D00559, D00633 D00633, D05575 D05575, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
116 |
Doxycycline |
Doxycycline |
5件: D00307 D00307, D02129 D02129, D03903 D03903, D03904 D03904, D07876 D07876 💬 |
- |
- |
013 15件: 13, 23, 28, 46, 84, 85, 89, 96, 97, 158, 162, 167, 227, 280, 299 💬 |
117 |
Doxycycline 100 mg capsules |
Doxycycline |
5件: D00307 D00307, D02129 D02129, D03903 D03903, D03904 D03904, D07876 D07876 💬 |
- |
- |
089 1件: 89 💬 |
118 |
Doxycycline 100-200mg capsules daily for 6 months |
Doxycycline |
5件: D00307 D00307, D02129 D02129, D03903 D03903, D03904 D03904, D07876 D07876 💬 |
- |
- |
167 1件: 167 💬 |
119 |
Doxycycline hyclate |
Doxycycline |
5件: D00307 D00307, D02129 D02129, D03903 D03903, D03904 D03904, D07876 D07876 💬 |
- |
- |
023 3件: 23, 96, 227 💬 |
120 |
Doxycycline hyclate ph.eur |
Doxycycline |
5件: D00307 D00307, D02129 D02129, D03903 D03903, D03904 D03904, D07876 D07876 💬 |
- |
- |
167 1件: 167 💬 |
121 |
Doxycycline tablets |
Doxycycline |
5件: D00307 D00307, D02129 D02129, D03903 D03903, D03904 D03904, D07876 D07876 💬 |
- |
- |
046 1件: 46 💬 |
122 |
Dual release hydrocortisone (plenadren) |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
123 |
Efi/act-385781a |
- |
- |
- |
- |
086 1件: 86 💬 |
124 |
Epoprostenol-actelion |
Epoprostenol |
2件: D00106 D00106, D01337 D01337 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
125 |
Etanercepet, rituximab, abatacept, tocilizumab, sarilumab |
Abatacept |
4件: D02596 D02596, D02994 D02994, D03203 D03203, D10161 D10161 💬 |
CD80 4件: CD80, CD86, IL6R, MS4A1 💬 |
Allograft rejection 24件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
126 |
Fentanyl |
Fentanyl |
2件: D00320 D00320, D01399 D01399 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
046 4件: 46, 70, 215, 231 💬 |
127 |
Fentanyl (high dose) |
Fentanyl |
2件: D00320 D00320, D01399 D01399 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
215 1件: 215 💬 |
128 |
Fentanyl (low dose) |
Fentanyl |
2件: D00320 D00320, D01399 D01399 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
215 1件: 215 💬 |
129 |
Fentanyl (low dose) + dexmedetomidine |
Dexmedetomidine |
4件: D00320 D00320, D00514 D00514, D01205 D01205, D01399 D01399 💬 |
ADRA2A 4件: ADRA2A, ADRA2B, ADRA2C, OPRM1 💬 |
Estrogen signaling pathway 4件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
215 1件: 215 💬 |
130 |
Fentanyl transdermal patch |
Fentanyl |
2件: D00320 D00320, D01399 D01399 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
131 |
Gene activated human glucocerebrosidase |
- |
- |
- |
- |
019 1件: 19 💬 |
132 |
Gene activated human glucocerebrosidase, velaglucerase alfa |
Velaglucerase alfa |
1件: D09029 D09029 💬 |
GBA 1件: GBA 💬 |
Lysosome 4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 1件: 19 💬 |
133 |
Gene-activated human glucocerebrosidase |
- |
- |
- |
- |
019 1件: 19 💬 |
134 |
Gene-activated human glucocerebrosidase 200u/vial |
- |
- |
- |
- |
019 1件: 19 💬 |
135 |
Gene-activated human glucocerebrosidase 400u/vial |
- |
- |
- |
- |
019 1件: 19 💬 |
136 |
H.p. acthar gel |
- |
- |
- |
- |
046 5件: 46, 49, 50, 84, 222 💬 |
137 |
H.p. acthar gel (repository corticotropin injection) |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
013 1件: 13 💬 |
138 |
H.p. acthar® gel |
- |
- |
- |
- |
014 1件: 14 💬 |
139 |
Hril-2 active |
- |
- |
- |
- |
046 3件: 46, 49, 53 💬 |
140 |
Hydrocortisone |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 9件: 6 , 46, 53, 75, 78, 81, 83, 97, 299 💬 |
141 |
Hydrocortisone (solucortef) |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
142 |
Hydrocortisone 100mg/ml |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
083 1件: 83 💬 |
143 |
Hydrocortisone 10mg |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
144 |
Hydrocortisone 10mg tablet |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
145 |
Hydrocortisone 10mg tablets |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
146 |
Hydrocortisone 20mg tablets |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
147 |
Hydrocortisone acetate |
Acetate |
2件: D00088 D00088, D00165 D00165 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
097 1件: 97 💬 |
148 |
Hydrocortisone cream |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
149 |
Hydrocortisone cream 1% |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
150 |
Hydrocortisone cream 10mg/g fna fagron |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
151 |
Hydrocortisone hydrogen succinate |
Hydrocortisone |
2件: D00088 D00088, D01442 D01442 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
083 1件: 83 💬 |
152 |
Hydrocortisone modified release capsules |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
153 |
Hydrocortisone roussel |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
083 1件: 83 💬 |
154 |
Hydrocortisone sodium acetate |
Acetate |
2件: D00088 D00088, D01779 D01779 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
155 |
Hydrocortisone sodium phosphate |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
053 3件: 53, 81, 83 💬 |
156 |
Hydrocortisone sodium succinate |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 3件: 81, 83, 97 💬 |
157 |
Hydrocortisone tablet 2.5 mg |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
158 |
Hydrocortisone takeda, tabletter |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
078 1件: 78 💬 |
159 |
Inn-tocilizumab |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
266 1件: 266 💬 |
160 |
Interferon beta 1a, oral doxycycline |
Doxycycline |
6件: D00307 D00307, D02129 D02129, D03903 D03903, D03904 D03904, D04554 D04554, D07876 D07876 💬 |
IFNAR1 2件: IFNAR1, IFNAR2 💬 |
Coronavirus disease - COVID-19 18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
013 1件: 13 💬 |
161 |
Interferon gamma-1b |
Interferon Gamma |
1件: D00747 D00747 💬 |
IFNGR1 2件: IFNGR1, IFNGR2 💬 |
Chagas disease 18件: Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis |
018 7件: 18, 65, 85, 228, 299, 301, 326 💬 |
162 |
Interferon gamma-1b (actimmune) |
Interferon Gamma |
1件: D00747 D00747 💬 |
IFNGR1 2件: IFNGR1, IFNGR2 💬 |
Chagas disease 18件: Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis |
085 1件: 85 💬 |
163 |
Intra-articular tocilizumab |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
164 |
Jnj-67896049 (act-293987) |
- |
- |
- |
- |
086 1件: 86 💬 |
165 |
Jnj-67896062 / act-064992 |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
166 |
Lamotrigin actavis |
- |
- |
- |
- |
114 1件: 114 💬 |
167 |
Long-acting somatostatin |
Somatostatin |
1件: D07431 D07431 💬 |
SSTR1 5件: SSTR1, SSTR2, SSTR3, SSTR4, SSTR5 💬 |
Gastric acid secretion 4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
067 1件: 67 💬 |
168 |
Macitentan (act-064992) |
Macitentan |
1件: D10135 D10135 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
169 |
Mesalazine with hydrocortisone sodium succinate |
Hydrocortisone |
2件: D00088 D00088, D00377 D00377 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
097 1件: 97 💬 |
170 |
Mra (actemra) |
- |
- |
- |
- |
107 1件: 107 💬 |
171 |
Mra (tocilizumab) |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 2件: 46, 107 💬 |
172 |
Mra(tocilizumab) |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 2件: 46, 107 💬 |
173 |
Mra, actemra |
- |
- |
- |
- |
046 2件: 46, 107 💬 |
174 |
Multi-modal pain management [fentanyl] |
Fentanyl |
2件: D00320 D00320, D01399 D01399 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
070 1件: 70 💬 |
175 |
Novorapid / humalog short acting insulin |
- |
- |
- |
- |
299 1件: 299 💬 |
176 |
Octreotide lar / sandostatin lar (lar=long acting release) |
Octreotide |
2件: D00442 D00442, D06495 D06495 💬 |
SSTR2 1件: SSTR2 💬 |
Gastric acid secretion 4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
084 1件: 84 💬 |
177 |
Other: corticotropin releasing hormone (crh) |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
078 1件: 78 💬 |
178 |
Other: fitbit activity monitor |
Methamidophos |
- |
- |
- |
049 1件: 49 💬 |
179 |
Other: hydrocortisone |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
075 1件: 75 💬 |
180 |
Other: low dose (1 mcg) acth stimulation test |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
193 1件: 193 💬 |
181 |
Other: no active treatment |
- |
- |
- |
- |
274 1件: 274 💬 |
182 |
Other: no doxycycline |
Doxycycline |
5件: D00307 D00307, D02129 D02129, D03903 D03903, D03904 D03904, D07876 D07876 💬 |
- |
- |
299 1件: 299 💬 |
183 |
Other: noninvasive actigraphy monitor |
Methamidophos |
- |
- |
- |
086 1件: 86 💬 |
184 |
Other: tampa kinesiophobia scale, berg-balance test, international physical activity questionnaire-short form, falls efficacy scale |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
185 |
Ovine corticotropin-releasing hormone (ocrh) |
Corticorelin |
2件: D00146 D00146, D03905 D03905 💬 |
CRHR1 3件: CRHR1, CRHR2, MC2R 💬 |
Aldosterone synthesis and secretion 6件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
075 1件: 75 💬 |
186 |
Pioglitazone |
Pioglitazone |
2件: D00945 D00945, D08378 D08378 💬 |
PPARG 1件: PPARG 💬 |
AMPK signaling pathway 9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
002 17件: 2 , 6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬 |
187 |
Pioglitazone 15 mg |
Pioglitazone |
2件: D00945 D00945, D08378 D08378 💬 |
PPARG 1件: PPARG 💬 |
AMPK signaling pathway 9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
096 1件: 96 💬 |
188 |
Pioglitazone and tretinoin |
Pioglitazone |
3件: D00094 D00094, D00945 D00945, D08378 D08378 💬 |
PML 4件: PML, PPARG, RARA, RARB 💬 |
AMPK signaling pathway 19件: AMPK signaling pathway, Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Huntington disease, Influenza A, Longevity regulating pathway, Non-small cell lung cancer, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis |
002 1件: 2 💬 |
189 |
Pioglitazone or metformin |
Metformin |
4件: D00944 D00944, D00945 D00945, D04966 D04966, D08378 D08378 💬 |
PPARG 3件: PPARG, PRKAA1, PRKAA2 💬 |
AMPK signaling pathway 25件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Huntington disease, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Osteoclast differentiation, Oxytocin signaling pathway, PI3K-Akt signaling pathway, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Tight junction, Transcriptional misregulation in cancer, mTOR signaling pathway |
265 1件: 265 💬 |
190 |
Procedure: embryonic dopamine cell implant surgery |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
191 |
Procedure: hydrocortisone withdrawal |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
192 |
Recombinant human cerebral dopamine neurotrophic factor |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
193 |
Reh-acteoside |
Acteoside |
- |
- |
- |
066 1件: 66 💬 |
194 |
Repository corticotropin injection |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
002 5件: 2 , 13, 46, 84, 222 💬 |
195 |
Repository corticotropin injection -treatment extension |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
084 1件: 84 💬 |
196 |
Risedronate sodium (actonel) |
Risedronic acid |
3件: D00942 D00942, D03234 D03234, D08484 D08484 💬 |
FDPS 1件: FDPS 💬 |
Human T-cell leukemia virus 1 infection 4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
274 1件: 274 💬 |
197 |
Risedronic acid |
Risedronic acid |
3件: D00942 D00942, D03234 D03234, D08484 D08484 💬 |
FDPS 1件: FDPS 💬 |
Human T-cell leukemia virus 1 infection 4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
093 3件: 93, 95, 274 💬 |
198 |
Rituximab, observational study amon patients with active ra |
Rituximab |
1件: D02994 D02994 💬 |
MS4A1 1件: MS4A1 💬 |
Hematopoietic cell lineage 1件: Hematopoietic cell lineage |
046 1件: 46 💬 |
199 |
Ro 47-0203 / act-050088 |
- |
- |
- |
- |
086 1件: 86 💬 |
200 |
Ro actemra |
- |
- |
- |
- |
046 1件: 46 💬 |
201 |
Ro-actemra |
- |
- |
- |
- |
046 1件: 46 💬 |
202 |
Ro47-0203 / act-050088 |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
203 |
Sar156597 (act14604) |
- |
- |
- |
- |
051 1件: 51 💬 |
204 |
Selexipag, act-293987 (ns-304) |
Selexipag |
1件: D09994 D09994 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
205 |
Short-acting insulin (actrapid) |
- |
- |
- |
- |
299 1件: 299 💬 |
206 |
Solu-cortef (hydrocortisone) |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
083 1件: 83 💬 |
207 |
Solu-cortef, powder for solution for injection, 100mg, and 'act-o-vial' |
- |
- |
- |
- |
006 1件: 6 💬 |
208 |
Standard analgesia use [fentanyl] |
Fentanyl |
2件: D00320 D00320, D01399 D01399 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
070 1件: 70 💬 |
209 |
Subcutaneous hydrocortisone |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
210 |
Subcutaneous hydrocortisone 10mg |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
211 |
Subcutaneous tocilizumab |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
212 |
Time and attention + active fructooligosaccharide supplementation |
- |
- |
- |
- |
096 1件: 96 💬 |
213 |
Tocilizumab |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
002 18件: 2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬 |
214 |
Tocilizumab (actemra or roactemra) |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
215 |
Tocilizumab (actemra) |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
216 |
Tocilizumab (actemra®) |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
217 |
Tocilizumab (mra-sc) |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
040 1件: 40 💬 |
218 |
Tocilizumab (tcz) |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 2件: 46, 56 💬 |
219 |
Tocilizumab + glucocorticoids (gcs) |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
041 1件: 41 💬 |
220 |
Tocilizumab + methotrexate(mtx) |
Methotrexate |
3件: D00142 D00142, D02115 D02115, D02596 D02596 💬 |
DHFR 3件: DHFR, DHFR2, IL6R 💬 |
Antifolate resistance 17件: Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
221 |
Tocilizumab 162 mg |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
222 |
Tocilizumab 162mg/0.9ml jeringa sc |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
223 |
Tocilizumab 162mg/0.9ml sc pfs sc |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
224 |
Tocilizumab 162mg/0.9ml syringe sc |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
225 |
Tocilizumab [roactemra/actemra] |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 4件: 46, 51, 107, 331 💬 |
226 |
Tocilizumab [roactemra] |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
227 |
Tocilizumab and iv steroids combination |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
041 1件: 41 💬 |
228 |
Tocilizumab infusion roacemtra (eu) |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
266 1件: 266 💬 |
229 |
Tocilizumab injection |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
013 1件: 13 💬 |
230 |
Tocilizumab iv |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
231 |
Tocilizumab plus methotrexate |
Methotrexate |
3件: D00142 D00142, D02115 D02115, D02596 D02596 💬 |
DHFR 3件: DHFR, DHFR2, IL6R 💬 |
Antifolate resistance 17件: Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
232 |
Tocilizumab prefilled syringe |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
233 |
Tocilizumab roche |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 2件: 46, 107 💬 |
234 |
Tocilizumab sc |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
041 3件: 41, 46, 107 💬 |
235 |
Tocilizumab sc 162 mg/0.9 ml disposable auto-injector (ai) |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
236 |
Tocilizumab sc 162 mg/0.9 ml pre-filled syringe with safety device (pfs) |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
237 |
Tocilizumab sc 162 mg/0.9 ml prefilled syringe with safety device (pfs) |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
051 1件: 51 💬 |
238 |
Tocilizumab treatment |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
041 1件: 41 💬 |
239 |
Tocilizumab+methotrexate(mtx) |
Methotrexate |
3件: D00142 D00142, D02115 D02115, D02596 D02596 💬 |
DHFR 3件: DHFR, DHFR2, IL6R 💬 |
Antifolate resistance 17件: Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
240 |
Tocilizumab, abatacept |
Abatacept |
2件: D02596 D02596, D03203 D03203 💬 |
CD80 3件: CD80, CD86, IL6R 💬 |
Allograft rejection 24件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor |
046 1件: 46 💬 |
241 |
Transdermal fentanyl matrix, gabapentin |
Fentanyl |
3件: D00320 D00320, D00332 D00332, D01399 D01399 💬 |
CACNA2D1 6件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, OPRM1, SLC6A1 💬 |
Adrenergic signaling in cardiomyocytes 12件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, Estrogen signaling pathway, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, Synaptic vesicle cycle |
070 1件: 70 💬 |
242 |
Treatment defined only by active substance |
- |
- |
- |
- |
050 1件: 50 💬 |
243 |
Treatment with systemic therapy (doxycycline) |
Doxycycline |
5件: D00307 D00307, D02129 D02129, D03903 D03903, D03904 D03904, D07876 D07876 💬 |
- |
- |
162 1件: 162 💬 |
244 |
Tretinoin and pioglitazone hcl |
Pioglitazone |
3件: D00094 D00094, D00945 D00945, D08378 D08378 💬 |
PML 4件: PML, PPARG, RARA, RARB 💬 |
AMPK signaling pathway 19件: AMPK signaling pathway, Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Huntington disease, Influenza A, Longevity regulating pathway, Non-small cell lung cancer, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis |
002 1件: 2 💬 |
245 |
Udca (ursodeoxycholic acid) |
Ursodeoxycholic acid |
1件: D00734 D00734 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
093 1件: 93 💬 |
246 |
Ursodeoxycholic acid |
Ursodeoxycholic acid |
1件: D00734 D00734 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
006 8件: 6 , 67, 84, 93, 94, 95, 96, 97 💬 |
247 |
Ursodeoxycholic acid (udca) |
Ursodeoxycholic acid |
1件: D00734 D00734 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
094 1件: 94 💬 |
248 |
Ursodeoxycholic acid (urso) |
Ursodeoxycholic acid |
1件: D00734 D00734 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
093 1件: 93 💬 |
249 |
Ursodeoxycholic acid 300mg capsule |
Ursodeoxycholic acid |
1件: D00734 D00734 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
093 1件: 93 💬 |
250 |
Ursodeoxycholic acid 300mg tablet |
Ursodeoxycholic acid |
1件: D00734 D00734 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
093 1件: 93 💬 |
251 |
Ursodeoxycholic acid capsules |
Ursodeoxycholic acid |
1件: D00734 D00734 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
093 1件: 93 💬 |
252 |
Ursodeoxycholic acid combination of immunosuppressive agents |
Ursodeoxycholic acid |
1件: D00734 D00734 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
093 2件: 93, 95 💬 |
253 |
Ursodeoxycholic acid combined with total glucosides of paeony |
Ursodeoxycholic acid |
1件: D00734 D00734 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
093 1件: 93 💬 |
254 |
Ursodeoxycholic acid only |
Ursodeoxycholic acid |
1件: D00734 D00734 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
093 1件: 93 💬 |
255 |
Ursodeoxycholic acid+low dose glucocorticoid(prednisone) |
Prednisone |
2件: D00473 D00473, D00734 D00734 💬 |
NR1H4 2件: NR1H4, NR3C1 💬 |
Bile secretion 2件: Bile secretion, Neuroactive ligand-receptor interaction |
093 1件: 93 💬 |
256 |
Ursodiol (ursodeoxycholic acid, udca) |
Ursodeoxycholic acid |
1件: D00734 D00734 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
097 1件: 97 💬 |
257 |
Uttr1147a/ro7021610 (active) |
- |
- |
- |
- |
096 2件: 96, 97 💬 |